Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment

American Journal of Hypertension

Volumn 17, Issue 12, 2004, Pages 1192-1200

  Schiffrin, Ernesto L ^a,b,c  

^a CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Angiotensin II; arterial remodeling; endothelial dysfunction; hypertension; resistance arteries

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; INDAPAMIDE; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTERY ENDOTHELIUM; ARTERY RESISTANCE; CLINICAL TRIAL; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ARTERIES; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIURETICS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; VASCULAR RESISTANCE;

EID: 11144307813     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.05.023     Document Type: Review

References (66)

1. P. Lund-Johanson Haemodynamics in early essential hypertension still an area of controversy J Hypertens 1 1983 209 213
2. H.G. Bohlen Localization of vascular resistance changes during hypertension Hypertension 8 1986 181 183
3. E.L. Schiffrin Reactivity of small blood vessels in hypertension relation with structural changes Hypertension 19 Suppl II 1992 II-1 II-9
4. E.L. Schiffrin Resistance arteries as endpoints in hypertension Blood Press 6 Suppl 2 1997 S24 S30
5. M.J. Mulvany, C. Aalkjaer Structure and function of small arteries Physiol Rev 70 1990 921 971
6. J.B. Park, E.L. Schiffrin Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension J Hypertens 19 2001 921 930
7. E.L. Schiffrin, L.Y. Deng Structure and function of resistance arteries of hypertensive patients treated with a β-blocker or a calcium channel antagonist J Hypertens 14 1996 1247 1255
8. D. Rizzoni, E. Porteri, G. Boari, C. De Ciuceis, I. Sleiman, M.L. Muiesan, M. Castellano, M. Miclini, E. Agabiti-Rosei Prognostic significance of small artery structure in hypertension Circulation 108 2003 2230 2235
9. J.B. Park, F. Charbonneau, E.L. Schiffrin Correlation of endothelial function in large and small arteries in human essential hypertension J Hypertens 19 2001 415 420
10. E.L. Schiffrin, J.B. Park, H.D. Intengan, R.M. Touyz Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin antagonist losartan Circulation 101 2000 1653 1659
11. E.L. Schiffrin, L.Y. Deng, P. Larochelle Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients Clin Invest Med 16 1993 177 186
12. D. Rizzoni, E. Porteri, D. Guefi, A. Piccoli, M. Castellano, G.M. Pasini, M.L. Muiesan, M.J. Mulvany, E. Agabiti-Rosei Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension Hypertension 35 2000 931 935
13. D. Rizzoni, E. Porteri, D. Guelfi, M.L. Muiesan, U. Valentini, A. Cimino, A. Girelli, L. Rodella, R. Bianchi, I. Sleiman, E. Agabiti Rosei Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus Circulation 103 2001 1238 1244
14. D.H. Endemann, Q. Pu, C. De Ciuceis, C. Savoia, A. Virdis, M.F. Neves, R.M. Touyz, E.L. Schiffrin Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment Hypertension 43 2004 399 404
15. D. Rizzoni, E. Porteri, A. Giustina, C. De Ciuceis, I. Sleiman, G.E.M. Boari, M. Castellano, M.L. Muiesan, S. Bonadonna, A. Burattin, B. Cerudelli, E. Agabiti-Rosei Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries Hypertension 43 2004 561 565
16. A.M. Sharifi, E.L. Schiffrin Apoptosis in vasculature of spontaneously hypertensive rats effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist Am J Hypertens 11 1998 1108 1116
17. H.D. Intengan, E.L. Schiffrin Structure and mechanical properties of resistance arteries in hypertension role of adhesion molecules and extracellular matrix determinants Hypertension 36 2000 312 318
18. A.M. Heagerty, C. Aalkjaer, S.J. Bund, N. Korsgaard, M.J. Mulvany Small artery structure in hypertension dual processes of remodelling and growth Hypertension 21 1993 391 397
19. E.N.T.P. Bakker, E.T. van der Meulen, B.M. van den Berg, V. Everts, J.A. Spaan, E. VanBavel Inward remodeling follows chronic vasoconstriction in isolated resistance arteries J Vasc Res 39 2002 12 20
20. H.D. Intengan, G. Thibault, J.S. Li, E.L. Schiffrin Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats effects of angiotensin receptor antagonism and converting enzyme inhibition Circulation 100 1999 2267 2275
21. H.D. Intengan, L.Y. Deng, J.S. Li, E.L. Schiffrin Mechanics and composition of human subcutaneous resistance arteries in essential hypertension Hypertension 33 1999 569 574
22. J.B. Park, E.L. Schiffrin Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats role of endothelin-1 Am J Hypertens 15 2002 164 169
23. R.M. Touyz, G. He, M. El Mabrouk, E.L. Schiffrin p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY Hypertension 37 2001 574 580
24. C.J. O'Callaghan, B. Williams The regulation of human vascular smooth muscle extracellular matrix protein production by α and β adrenoceptor stimulation J Hypertens 20 2002 287 294
25. C. Laviades, N. Varo, J. Fernández, G. Mayor, M.J. Gil, I. Monreal, J. Diez Abnormalities of the extracellular degradation of collagen type I in essential hypertension Circulation 98 1998 535 540
26. R.M. Touyz, E.L. Schiffrin Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells Pharmacol Rev 52 2000 639 672
27. R.M. Touyz, G. Yao, E.L. Schiffrin c-Src induces phosphorylation and translocation of p47phox role in superoxide generation by Ang II in human vascular smooth muscle cells Arterioscler Thromb Vasc Biol 23 2003 981 987
28. C. Fernandez-Patron, M.W. Radomski, S.T. Davidge Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor Circ Res 85 1999 906 911
29. E.L. Schiffrin Role of endothelin-1 in hypertension Hypertension 34 1999 876 881
30. U. Landmesser, S. Dikalov, S.R. Price, L. McCann, T. Fukai, S.M. Holland, W.E. Mitch, D.G. Harrison Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension J Clin Invest 111 2003 1201 1209
31. M.R. Tschudi, S. Mesaros, T.F. Lüscher, T. Malinski Direct in situ measurement of nitric oxide in mesenteric resistance arteries Hypertension 27 1996 32 35
32. D.A. Diederich, Z. Yang, F.R. Bühler, T.F. Lüscher Impaired endothelium-dependent relaxations in hypertensive small arteries involve the cyclooxygenase pathway Am J Physiol Heart Circ Physiol 258 1990 H445 H551
33. 3 integrin mediates arteriolar vasodilation in response to RGD peptides Circ Res 79 1996 821 826
34. H. Miettinen, S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects Stroke 27 1996 2033 2039
35. A. Greene, P.J. Tonellato, J. Lui, J.H. Lombard, A.W. Cowley Jr Microvascular rarefaction and tissue vascular resistance in hypertension Am J Physiol Heart Circ Physiol 256 1989 H126 H131
36. I. Hernandez, A.W. Cowley Jr, J.H. Lombard, A.S. Greene Salt intake and angiotensin II alter microvessel density in the cremaster muscle of normal rats Am J Physiol Heart Circ Physiol 263 1992 H664 H667
37. E.H. Serné, R.O.B. Gans, J.C. ter Maaten, G.J. Tangelder, A.J. Donker, C.D. Stehouwer Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction Hypertension 38 2001 238 242
38. S.A. Griffin, W.C.B. Brown, F. MacPherson, J.C. McGrath, V.G. Wilson, N. Korsgaard, M.J. Mulvany, A.F. Lever Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism Hypertension 17 1991 626 635
39. D. Rizzoni, M.L. Muiesan, E. Porteri, M. Castellano, R. Zulli, G. Bettoni, M. Salvetti, C. Monteduro, E. Agabiti-Rosei Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy J Hypertens 15 1997 197 204
40. L. Ghiadoni, A. Virdis, A. Magagna, S. Taddei, A. Salvetti Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension Hypertension 35 2000 501 506
41. M. Shargorodsky, E. Leibovitz, L. Lubimov, D. Gavish, R. Zimlichman Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension Am J Hypertens 15 2002 1087 1091
42. B. Schwartzkopff, M. Brehm, M. Mundhenke, B.E. Strauer Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease Hypertension 36 2000 220 225
43. R.M. Carey, N.L. Howell, X.H. Jin, H.M. Siragy Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats Hypertension 38 2001 1272 1277
44. L. Wu, M. Iwai, H. Nakagami, Z. Li, R. Chen, J. Suzuki, M. Akishita, M. de Gasparo, M. Horiuchi Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury Circulation 104 2001 2716 2721
45. E.L. Schiffrin, L.Y. Deng, P. Larochelle Effects of a beta blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension Hypertension 23 1994 83 91
46. E.L. Schiffrin, J.B. Park, Q. Pu Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function J Hypertens 20 2002 71 78
47. E.L. Schiffrin, D. Hayoz How to assess vascular remodelling in small and medium-sized muscular arteries in humans J Hypertens 15 1997 571 584
48. J.M. Ledingham, E.L. Phelan, M.A. Cross, R. Laverty Prevention of increases in blood pressure and left ventricular mass and remodeling of resistance arteries in young New Zealand genetically hypertensive rats the effects of chronic treatment with valsartan, enalapril and felodipine J Vasc Res 37 2000 134 145
49. J. Mann, S. Julius VALUE Group The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension rationale and design Blood Press 7 1998 176 183
50. S. Julius, S.E. Kjeldsen, H. Brunner, L. Hansson, F. Platt, S. Ekman, J.H. Laragh, G. McInnes, A.M. Schork, B. Smith, M. Weber, A. Zanchetti VALUE Trial Investigators VALUE trial long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk Am J Hypertens 16 2003 544 548
51. E.L. Schiffrin, L.Y. Deng, P. Larochelle Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin converting enzyme inhibitor comparison with effects of a beta blocker Am J Hypertens 8 1995 229 236
52. N.K. Thybo, N. Stephens, A. Cooper, C. Aalkjaer, A.M. Heagerty, M.J. Mulvany Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension Hypertension 25 1995 474 481
53. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
54. E.L. Schiffrin, Q. Pu, J.B. Park Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients Am J Hypertens 15 2002 105 110
55. The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
56. I. Sihm, A.P. Schroeder, C. Aalkjaer, M.J. Mulvany, K. Thygesen, O. Lederballe Effect of antihypertensive treatment on cardiac and subcutaneous artery structure a comparison between calcium channel blocker and thiazide-based regimens Am J Hypertens 11 1998 263 271
57. L.M. Wing, C.M. Reid, P. Ryan, L.J. Beilin, M.A. Brown, G.L. Jennings, C.I. Johnston, J.J. McNeil, G.J. Macdonald, J.E. Marley, T.O. Morgan, M.J. West Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592
58. V. Richard, R. Joannides, J.P. Henry, P. Mulder, B. Mace, D. Guez, P. Schiavi, C. Thuillez Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats haemodynamic, biological and structural effects J Hypertens 14 1996 1447 1454
59. J.-M. Chillon, G.L. Baumbach Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats Hypertension 43 2004 1092 1097
60. J. Chalmers, S. MacMahon PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
61. B. Neal, S. MacMahon, N. Chapman Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs results of prospectively designed overviews of randomised trials Lancet 356 2000 1955 1964
62. J.A. Staessen, Y.G. Wang, L. Thijs Cardiovascular protection and blood pressure reduction a meta-analysis Lancet 358 2001 1305 1315
63. F. Turnbull Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
64. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
65. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, I. Raz Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
66. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259